OBR OncologyCould New Oncology Agents Change Standards of Care?

Not surprisingly, given the rate at which new FDA approvals are granted, the majority of clinicians prescribed a newly FDA-approved drug in the previous year, with 20% prescribing at least ten new drugs, according to OBRs Oncology Drug Report 2022. The latter metric demonstrates how quickly the world of cancer care is evolving, which has a number of important implications for oncology practice.